Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine

• Autor(a) principal: Zugno,Alexandra I.
• Data de Publicação: 2012
• Outros Autores: Barcelos,Mariely, Oliveira,Larissa de, Canever,Leila, Luca,Renata D. de, Fraga,Daiane B., Matos,Maria Paula, Rezin,Gislaine T., Scaini,Giselli, Búrigo,Márcio, Streck,Emilio L., Quevedo,João
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000200009
• topic: schizophrenia; olanzapine; cafeteria diet; energy metabolism; leptin

OBJECTIVES: Olanzapine, an atypical antipsychotic drug with affinities for dopamine, serotonin, and histamine binding sites appears to be associated with substantial weight gain and metabolic alterations. The aim of this study was to evaluate weight gain and metabolic alterations in rats treated with olanzapine on a hypercaloric diet. METHODS: We used 40 rats divided into 4 groups: Group 1, standard food and water conditions (control); Group 2, standard diet plus olanzapine; Group 3, cafeteria diet (hypercaloric); and Group 4, olanzapine plus cafeteria diet. Olanzapine was administered by gavage at a dose of 3 mg/kg for 9 weeks. RESULTS There were no significant changes in the cholesterol levels in any group. Glucose levels increased in Group 3 by the fourth week. Triglyceride levels were altered in group 2 toward the end of the experiment. Leptin levels decreased in Groups 2 and 4. Complex II activity in the muscles and liver was altered in Group 2 (muscle), and Groups 2, 3, and 4 (liver). Complex IV activity was altered only in the liver in Group 2, without significant alterations within the muscles. CONCLUSION: These results suggest that olanzapine is correlated with weight gain and the risks associated with obesity.